



# NECTAR LIFESCIENCES LIMITED

Regd. Office : Vill. Saidpura, Tehsil Derabassi, Distt. Mohali (Punjab)

**Un-audited Financial Results for the Quarter ended 31.12.2011** (Rs. in Lacs)

| S No. | PARTICULARS   | Quarter ended 31.12.2011 | Quarter ended 30.09.2011 | Quarter ended 31.12.2010 | 9 Months Ended 31.12.2011 | 9 Months Ended 31.12.2010 | Year Ended 31.03.2011 |
|-------|---|--------------------------|--------------------------|--------------------------|---------------------------|---------------------------|-----------------------|
|       |   | Un-audited               | Un-audited               | Un-audited               | Un-audited                | Un-audited                | Audited               |
| 1.    | <b>Gross Sales/Income from Operations</b>   | 41711.79                 | 29937.20                 | 33786.46                 | 93556.36                  | 75932.12                  | 111577.03             |
|       | Less : Excise Duty  | 719.24                   | 919.70                   | 1743.21                  | 2656.77                   | 4191.48                   | 6032.19               |
|       | Net Sales / Income from Operations  | 40992.55                 | 29017.50                 | 32043.25                 | 90899.59                  | 71740.64                  | 105544.84             |
|       | Other Operating Income  | 164.47                   | 238.55                   | 236.82                   | 643.60                    | 445.54                    | 661.44                |
|       | <b>Total Operating Income</b>   | <b>41157.02</b>          | <b>29256.05</b>          | <b>32280.07</b>          | <b>91543.19</b>           | <b>72186.18</b>           | <b>106206.28</b>      |
| 2.    | <b>Expenditure</b>  |                          |                          |                          |                           |                           |                       |
|       | a. (Increase)/decrease in stock in trade  | 530.37                   | (444.93)                 | (803.90)                 | (84.60)                   | (2492.08)                 | (3162.81)             |
|       | b. Consumption of Raw Material  | 28646.10                 | 20577.73                 | 22817.12                 | 62656.31                  | 49044.53                  | 74269.80              |
|       | c. Employees Cost   | 1221.82                  | 1234.39                  | 1090.45                  | 3696.56                   | 2868.53                   | 3716.81               |
|       | d. Depreciation   | 1663.36                  | 1608.57                  | 1164.31                  | 4497.27                   | 3435.50                   | 4609.59               |
|       | e. Other Expenditure  | 3288.82                  | 2163.85                  | 2341.95                  | 7593.74                   | 6011.18                   | 8694.38               |
|       | <b>Total Expenditure</b>  | <b>35350.47</b>          | <b>25139.61</b>          | <b>26609.93</b>          | <b>78359.28</b>           | <b>58867.66</b>           | <b>88127.77</b>       |
| 3.    | <b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b> | <b>5806.55</b>           | <b>4116.44</b>           | <b>5670.14</b>           | <b>13183.91</b>           | <b>13318.52</b>           | <b>18078.51</b>       |
| 4.    | Other Income  | 412.18                   | 450.57                   | 12.53                    | 862.83                    | 18.24                     | 1345.58               |
| 5.    | <b>Profit before Interest &amp; Exceptional Items (3+4)</b>                               | <b>6218.73</b>           | <b>4567.01</b>           | <b>5682.67</b>           | <b>14046.74</b>           | <b>13336.76</b>           | <b>19424.09</b>       |
| 6.    | Interest  | 2542.82                  | 2107.77                  | 1567.30                  | 6610.95                   | 4185.67                   | 7408.40               |
| 7.    | <b>Profit after Interest but before Exceptional Items (5-6)</b>                           | <b>3675.91</b>           | <b>2459.24</b>           | <b>4115.37</b>           | <b>7435.79</b>            | <b>9151.09</b>            | <b>12015.69</b>       |
| 8.    | Exceptional Items   | 0.00                     | 0.00                     | 0.00                     | 0.00                      | 0.00                      | 0.00                  |
| 9.    | <b>Profit from ordinary activities before tax (7+8)</b>                                   | <b>3675.91</b>           | <b>2459.24</b>           | <b>4115.37</b>           | <b>7435.79</b>            | <b>9151.09</b>            | <b>12015.69</b>       |
| 10.   | <b>Tax Expenses</b>   | 436.94                   | 328.94                   | 1093.85                  | 944.54                    | 2146.37                   | 1734.68               |
| 11.   | <b>Net Profit from ordinary activities after tax (9-10)</b>                               | <b>3238.97</b>           | <b>2130.30</b>           | <b>3021.52</b>           | <b>6491.25</b>            | <b>7004.72</b>            | <b>10281.01</b>       |
| 12.   | Extraordinary Item (net of tax expense)   | 0.00                     | 0.00                     | 0.00                     | 0.00                      | 0.00                      | 0.00                  |
| 13.   | <b>Net Profit for the period (11-12)</b>  | <b>3238.97</b>           | <b>2130.30</b>           | <b>3021.52</b>           | <b>6491.25</b>            | <b>7004.72</b>            | <b>10281.01</b>       |
| 14.   | Paid up Equity Share Capital (Face Value per share : Re.1/-)                              | 2242.61                  | 2242.61                  | 2242.61                  | 2242.61                   | 2242.61                   | 2242.61               |
| 15.   | Reserves excluding Revaluation Reserves   |                          |                          |                          |                           |                           | 69875.75              |
| 16.   | <b>Earnings per Share (EPS)</b>   |                          |                          |                          |                           |                           |                       |
|       | Basic EPS before Extraordinary items  | 1.44                     | 0.95                     | 1.35                     | 2.89                      | 3.12                      | 4.63                  |
|       | Diluted EPS before Extraordinary items  | 1.44                     | 0.95                     | 1.07                     | 2.89                      | 2.49                      | 4.63                  |
|       | Basic EPS after Extraordinary items   | 1.44                     | 0.95                     | 1.35                     | 2.89                      | 3.12                      | 4.63                  |
|       | Diluted EPS after Extraordinary items   | 1.44                     | 0.95                     | 1.07                     | 2.89                      | 2.49                      | 4.63                  |
| 17.   | <b>Public Shareholding</b>  |                          |                          |                          |                           |                           |                       |
|       | - Number of Shares  | 124856970                | 124896970                | 125246970                | 124856970                 | 125246970                 | 124969970             |
|       | - Percentage of Shareholding  | 55.67                    | 55.69                    | 55.85                    | 55.67                     | 55.85                     | 55.73                 |
| 18.   | <b>Promoters &amp; Promoter Group Shareholding</b>  |                          |                          |                          |                           |                           |                       |
|       | <b>a) Pledged/Encumbered</b>  |                          |                          |                          |                           |                           |                       |
|       | - Number of Shares  | 0                        | 0                        | 0                        | 0                         | 0                         | 0                     |
|       | - Percentage of Shares ( as a % of the total shareholding of promoter and promoter group) | 0.00                     | 0.00                     | 0.00                     | 0.00                      | 0.00                      | 0.00                  |
|       | - Percentage of Shares ( as a % of the total share capital of the company)                | 0.00                     | 0.00                     | 0.00                     | 0.00                      | 0.00                      | 0.00                  |
|       | <b>b) Non-encumbered</b>  |                          |                          |                          |                           |                           |                       |
|       | - Number of Shares  | 99404000                 | 99364000                 | 99014000                 | 99404000                  | 99014000                  | 99291000              |
|       | - Percentage of Shares ( as a % of the total shareholding of promoter and promoter group) | 100.00                   | 100.00                   | 100.00                   | 100.00                    | 100.00                    | 100.00                |
|       | - Percentage of Shares (as a % of the total share capital of the company)                 | 44.33                    | 44.31                    | 44.15                    | 44.33                     | 44.15                     | 44.27                 |

**Notes :** 1. The above financial results were reviewed by Audit Committee on 10.02.2012 and approved by the Board in its meeting held on even date i.e. 10.02.2012 and further limited reviewed by the Statutory Auditors of the Company.

2. The company is exclusively in the pharmaceutical business segment.
3. The above financial results are on stand alone basis.
4. As required by the Accounting Standard -11 on "The effect of change in foreign exchange rates" , there is a notional loss on foreign currency loans during the quarter, which would be recognised, if any, at the end of accounting year.
5. Status of Complaints:
 

|  |  |
|--|--|
| a) Pending at the beginning of Quarter - Nil | b) Received During the Quarter - 11    |
| c) Disposed Off During the Quarter - 11      | d) Pending at the end of Quarter - Nil |

**By Order of the Board of Directors  
of Nectar Lifesciences Limited**

Sd/-

(Sanjiv Goyal)

**Chairman and Managing Director**

**Dated : 10.02.2012**

**Place : Chandigarh**